|
Gene: NUP210L |
Gene summary for NUP210L |
Gene summary. |
Gene information | Species | Human | Gene symbol | NUP210L | Gene ID | 91181 |
Gene name | nucleoporin 210 like | |
Gene Alias | NUP210L | |
Cytomap | 1q21.3 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q5VU65 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
91181 | NUP210L | EEC-subject1 | Human | Endometrium | EEC | 1.34e-09 | 4.04e-01 | -0.2682 |
91181 | NUP210L | EEC-subject4 | Human | Endometrium | EEC | 6.22e-03 | 2.22e-01 | -0.2571 |
91181 | NUP210L | RNA-P17T-P17T-4 | Human | Lung | IAC | 1.48e-03 | 5.91e-01 | 0.343 |
91181 | NUP210L | RNA-P17T-P17T-6 | Human | Lung | IAC | 1.48e-03 | 5.52e-01 | 0.3385 |
91181 | NUP210L | RNA-P17T-P17T-8 | Human | Lung | IAC | 1.55e-04 | 4.29e-01 | 0.3329 |
91181 | NUP210L | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 4.20e-04 | 2.27e-01 | -0.0166 |
91181 | NUP210L | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 1.06e-02 | 1.67e-01 | -0.0132 |
91181 | NUP210L | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 4.32e-03 | 1.48e-01 | -0.013 |
91181 | NUP210L | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 6.25e-03 | 1.80e-01 | -0.0121 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501425 | Endometrium | EEC | Amyotrophic lateral sclerosis | 128/1237 | 364/8465 | 9.83e-24 | 4.04e-22 | 3.01e-22 | 128 |
hsa0501435 | Endometrium | EEC | Amyotrophic lateral sclerosis | 128/1237 | 364/8465 | 9.83e-24 | 4.04e-22 | 3.01e-22 | 128 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NUP210L | SNV | Missense_Mutation | c.1396A>T | p.Met466Leu | p.M466L | Q5VU65 | protein_coding | tolerated(0.72) | benign(0) | TCGA-55-7724-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
NUP210L | SNV | Missense_Mutation | novel | c.2165N>C | p.Gln722Pro | p.Q722P | Q5VU65 | protein_coding | tolerated(0.13) | benign(0.026) | TCGA-67-3771-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NUP210L | SNV | Missense_Mutation | c.3948N>T | p.Arg1316Ser | p.R1316S | Q5VU65 | protein_coding | deleterious(0.01) | possibly_damaging(0.541) | TCGA-67-6217-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Targeted Molecular therapy | tarceva | SD | |
NUP210L | SNV | Missense_Mutation | c.5046N>T | p.Lys1682Asn | p.K1682N | Q5VU65 | protein_coding | tolerated(0.12) | benign(0.071) | TCGA-78-7158-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD | |
NUP210L | SNV | Missense_Mutation | c.2219G>T | p.Gly740Val | p.G740V | Q5VU65 | protein_coding | deleterious(0.02) | possibly_damaging(0.834) | TCGA-78-7536-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | |
NUP210L | SNV | Missense_Mutation | c.4867A>G | p.Thr1623Ala | p.T1623A | Q5VU65 | protein_coding | tolerated(0.77) | probably_damaging(0.985) | TCGA-91-6836-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
NUP210L | SNV | Missense_Mutation | c.889N>A | p.Gln297Lys | p.Q297K | Q5VU65 | protein_coding | tolerated(0.09) | benign(0.164) | TCGA-95-7039-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
NUP210L | SNV | Missense_Mutation | novel | c.1146C>A | p.Asp382Glu | p.D382E | Q5VU65 | protein_coding | tolerated(1) | benign(0) | TCGA-MN-A4N1-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
NUP210L | SNV | Missense_Mutation | c.1250G>T | p.Gly417Val | p.G417V | Q5VU65 | protein_coding | deleterious(0.01) | possibly_damaging(0.762) | TCGA-18-3411-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
NUP210L | SNV | Missense_Mutation | novel | c.4303N>T | p.Asp1435Tyr | p.D1435Y | Q5VU65 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-21-1082-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |